undamentalytics Newsletter
Sign in

Artiva Biotherapeutics, Inc. balance sheet

At the end of fiscal 2025, Artiva Biotherapeutics, Inc. had total assets of $131m, total liabilities of $21.0m and shareholders' equity of $110m. It held $26.7m in cash against $0 of debt: net cash of $26.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents544027
Receivables10—
Total current assets80189113
Total assets105210131
Accounts payable110
Total current liabilities121213
Total debt000
Total liabilities512321
Shareholders' equity−162187110
Non-controlling interests and other (assets − liabilities − equity)216——
Net debt (negative = net cash)−54−40−27

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ARTV vs CLNNARTV vs CRVOARTV vs CLDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Artiva Biotherapeutics, Inc.